BAT 8010
Alternative Names: BAT-8010Latest Information Update: 21 Jul 2026
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 02 Jun 2026 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 30 May 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 08 May 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable) in China (IV) ((NCT06376136) )